Table 5.

ORs and 95% CIs for the Association Between Chemotherapy With Alkylating and Nonalkylating Agents and Risk of Congenital Anomalies in the Offspring of Female and Male Childhood Cancer Survivors

Treatment Group	Congenital Anomaly Outcome (n)	All Offspring (n)	Proportion With Anomalies (%)	Crude OR	95% CI	OR*	95% CI
Females, AAD score†
No chemo treatment	24	696	3.4	1.0	Referent	1.0	Referent
0 (nonalkylator only)	18	668	2.7	0.77	0.40 to 1.48	0.73	0.37 to 1.44
1	10	441	2.3	0.66	0.31 to 1.39	0.63	0.29 to 1.37
2	13	370	3.5	1.03	0.52 to 2.03	1.00	0.49 to 2.03
3	13	330	3.9	1.15	0.58 to 2.26	1.13	0.57 to 2.25
Ptrend				.68		.69
Males, AAD score†
No chemo treatment	12	574	2.1	1.0	Referent	1.0	Referent
0 (nonalkylator only)	8	455	1.8	0.83	0.32 to 2.16	0.92	0.32 to 2.59
1	10	398	2.5	1.16	0.50 to 2.70	1.29	0.52 to 3.22
2 or 3‡	4	335	1.2	0.57	0.18 to 1.79	0.59	0.19 to 1.86
Ptrend				.55		.62

Abbreviation: OR, odds ratio.

^*ORs adjusted for calendar year of birth and maternal age (for the female analyses) and for calendar year of birth and paternal age (for the male analyses).

^†Alkylating agent dose score, see Methods for definition.

^‡Scores 2 and 3 were grouped because of small numbers.